- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01197053
Epicutaneous Immunotherapy in Peanut Allergy in Children (ARACHILD)
ARACHILD: A Multicentric, Double Blind Placebo-controlled Pilot Protocol to Study the Efficacy and Safety of an Epicutaneous Immunotherapy in Children Allergic to Peanut
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Peanut allergy is a common allergy in the United Sates, with prevalence in the general population as high as 1%. Peanut allergy starts in childhood, its prevalence in children has doubled in the past 5 years, and barely 20% of the allergic children will outgrow this allergy So far, the only treatments available for peanut allergy are avoidance of peanut and injectable epinephrine after the allergic systemic reactions have started. Immunotherapy methods currently available have shown some limitations in their use because of important safety issues. Hence, there is an important unmet medical need for efficient and safe treatment of peanut allergy.
DBV Technologies, is a French biotech company which has developed an Epicutaneous Delivery System, called Viaskin®, a method based on delivering precise quantity of allergens on the upper layers of the skin, i.e. on the epidermis and without any passage in the vascularised dermis. Avoiding contact between the allergens and the bloodstream should confer to epicutaneous immunotherapy (EPIT) a high level of safety as systemic reactions are circumvented.
The goal of this pilot study is to demonstrate that epicutaneous immunotherapy (EPIT) with Viaskin® is safe and efficacious for the desensitization of peanut-allergic children, i.e. increasing the quantity of peanut proteins they can consume symptom-free.
Fifty-two (52) children from 5 to 17 years of age with a confirmed peanut allergy during a baseline double blind placebo-controlled food challenge (DBPCFC) (reacting to a capped value below 250 mg of peanut proteins) will be randomized 1 to 1 and treated either with DBV712, the Viaskin® disk loaded with 100 mcg peanut proteins (active treatment), or with placebo, the Viaskin® disk loaded with a placebo formulation devoid of peanut. Each child will receive one application of one Viaskin® on the skin every day repeatedly for 6 months in a blinded manner, followed by a 12-month open treatment with DBV712 for all of them; placebo children will all cross-over after the first 6 months of treatment to also receive the active treatment.
A DBPCFC to peanut will then be conducted after every 6 months of treatment to assess the efficacy of the treatment. Safety will be assessed during the whole study period.
Skin testing, peanut-specific IgE and IgG4 will occur at selected visits
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Paris, France, 75015
- Hôpital Necker
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male or Female between 5 and 17 years of age at enrollment
- An efficient contraceptive method for girls with childbearing potential. Acceptable methods include sexual abstinence, oral, injectable contraceptive methods, intra uterine device.
- Negative pregnancy test for girls with childbearing potential.
- Child with a documented allergy to peanut, i.e. with peanut-specific IgE (>5KU/L, ImmunoCAP method) and/or a positive skin prick test to peanut (wheal diameter ≥ 8mm).
- Child able to consume a cumulated quantity of peanut proteins <250 mg during the baseline DBPCFC.
- Child and his/her legal representative(s) who provide a signed consent form and assent form.
- Child and his/her legal representative(s) whose family and social conditions allow them to understand the protocol and agree to comply in the long term with all study requirements.
Exclusion criteria :
- Child considered too severely allergic to peanut: with a history of severe anaphylaxis to peanut (with hypotension, loss of consciousness, severe bradycardia, respiratory or cardiac arrest requiring an admission to emergency rooms).
- Child with peanut-specific IgE<5 KU/L and whose skin prick test to peanut gave a wheal diameter <8mm).
- Child participating or having participated in a therapeutic study in the last 3 months
- Pregnancy or Breastfeeding
- Child with a generalized eczema
- Child with an immune deficiency
- Diabetic child
- Child allergic to chocolate
- Child or legal representative(s) who did not sign their consent or assent
- Child with no baseline DBPCFC
- Child having reacted to placebo during the baseline DBPCFC
- Child able to consume > 250 mg of cumulated peanut proteins during the baseline DBPCFC
- Child with a respiratory deficiency or with an uncontrolled asthma.
- Child who could not discontinue oral or I.V. antihistamines or oral or I.V. corticosteroids at least the week prior to Visit 1.
- Child with important skin lesions precluding the application of the disks.
- Child not affiliated to social security.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: CROSSOVER
- Masking: DOUBLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: 100 mcg DBV712 (active)
100 mcg DBV712 administered epicutaneously every 24 hours.
|
100 mcg peanut proteins (active arm) applied on the skin every 24 hrs for 6 months blinded, followed by 12 months open treatment for all patients in the active arm
|
PLACEBO_COMPARATOR: Placebo
Placebo will be administered epicutaneously every 24 hours
|
placebo applied on the skin every 24 hrs for 6 months blinded, followed by 12 months open treatment for all patients in the active arm
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Proportion of patients able to consume >1000 mg of peanut proteins symptom-free
Time Frame: 6 months
|
Proportion of patients able to consume >1000 mg of peanut proteins symptom-free during the double blind placebo-controlled food challenges (DBPCFC) to peanut at 6 months, or who have a 10-fold increase in the quantity of peanut proteins consumed as compared to baseline value
|
6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Description of the level of Ig
Time Frame: 6 months
|
|
6 months
|
Proportion of patients able to consume >1000 mg of peanut proteins symptom-free
Time Frame: 12 months
|
-Proportion of patients able to consume >1000 mg of peanut proteins symptom-free during the double blind placebo-controlled food challenges (DBPCFC) to peanut at 12 months
|
12 months
|
Proportion of patients able to consume >1000 mg of peanut proteins symptom-free
Time Frame: 18 months
|
-Proportion of patients able to consume >1000 mg of peanut proteins symptom-free during the double blind placebo-controlled food challenges (DBPCFC) to peanut at 18 months
|
18 months
|
diameter and safety
Time Frame: 3, 6, 12 and 18 months
|
|
3, 6, 12 and 18 months
|
Collaborators and Investigators
Collaborators
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- P091102
- 2010-019541-26 (EUDRACT_NUMBER)
- A100293-36 (OTHER: AFSSAPS)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Peanut Allergy
-
Rima RachidUniversity of MinnesotaRecruitingPeanut Hypersensitivity | Peanut Allergy | Food Allergy | Food Allergy Peanut | Peanut-Induced Anaphylaxis | Allergy, PeanutUnited States
-
Scripps HealthThe Scripps Research InstituteWithdrawnFood Allergy PeanutUnited States
-
Novartis PharmaceuticalsTerminatedAllergy, PeanutUnited States, Germany, Japan, Australia, France, Spain, Denmark, Canada, Italy, Netherlands
-
University of ManitobaThe Hospital for Sick Children; University of British Columbia; McGill UniversityEnrolling by invitationAllergy to Peanut
-
Imperial College LondonUniversity of Sydney; National Institute for Health Research, United KingdomCompletedIgE Mediated Peanut AllergyUnited Kingdom
-
King's College LondonCharite University, Berlin, Germany; University Hospital, Bonn; Institut Curie; Levantine UKNot yet recruitingAllergy;Food | Food Allergy Peanut | Pathways and Sources of Exposure
-
Imperial College LondonUniversity College CorkActive, not recruitingPeanut Hypersensitivity | IgE Mediated Peanut AllergyUnited Kingdom
-
University of RochesterNational Institute of Allergy and Infectious Diseases (NIAID)Not yet recruitingEgg Allergy | Food Allergy Peanut | Food Allergy in Infants | Allergy and Immunology | Peanut and Nut AllergyUnited States
-
National Institute of Allergy and Infectious Diseases...Genentech, Inc.; Novartis Pharmaceuticals; Rho Federal Systems Division, Inc.Active, not recruitingPeanut Allergy | Multi-food AllergyUnited States
-
Scott SichererNational Institute of Allergy and Infectious Diseases (NIAID)CompletedPeanut Allergy | Food AllergyUnited States
Clinical Trials on Epicutaneous Immunotherapy
-
Children's Hospital of PhiladelphiaDBV TechnologiesCompletedEosinophilic Esophagitis | Milk AllergyUnited States
-
AllerdermCompletedDermatitis, EczematousJapan, United States, Germany, Italy, Netherlands, Switzerland
-
University of North Carolina, Chapel HillNorth Carolina Agriculture & Technical State UniversityCompletedPeanut AllergyUnited States
-
Power Life Sciences Inc.Not yet recruiting
-
Leti Pharma GmbHCompletedAllergic Asthma | Allergic RhinoconjunctivitisGermany
-
University Hospital Center of MartiniqueEuropean Georges Pompidou HospitalCompletedImmunotherapyFrance, Martinique
-
Washington University School of MedicineUnknownMelanoma | Skin Cancer | Merkel Cell Carcinoma | Basal Cell Carcinoma | Squamous Cell Carcinoma of the Skin | AutoimmunityUnited States
-
Guangdong Association of Clinical TrialsRecruitingLung Cancer | ImmunotherapyChina
-
National Guard Health AffairsUnknown